New Alzheimer’s treatment data release sends Biogen stock down 3.78%

New Alzheimer’s treatment data release sends Biogen stock down 3.78%
Biogen slides 3.78% today

Biogen announced it is sharing new real-world data at ADPD2026, together with Eisai. The data evaluates long-term treatment persistence in the U.S. among people living with early Alzheimer's disease.

Highlights

  • BIIB trades below short- and medium-term moving averages, indicating ongoing seller pressure despite a solid long-term support base.
  • Momentum indicators on daily timeframes flash bearish to neutral, but weekly signals point strongly bullish with high probability of an upward move.
  • Expected range for next week is $179.74 to $187.00, with potential for consolidation unless $189 resistance is reclaimed or $178 support is breached.

Biogen provided a link to read more about the announcement. Details are being clarified.

BIIB is trading at $183.84, sitting below both the MA-20 ($185.80) and MA-50 ($184.80), indicating short- and medium-term pressure from sellers, but remains well above the MA-200 ($158.20), showing long-term support is still intact. The Ichimoku Kijun on D1 stands at $189.53, which acts as immediate resistance, while near-term support is at MA-50 ($184.80) and key support at MA-100 ($178.91); resistance levels cluster at the Kijun ($189.53) and MA-20 ($185.80).

Momentum signals are bearish, with MACD on D1 showing a strong sell bias and ADX remaining neutral, suggesting that negative momentum lacks strong conviction. RSI on D1 reads 47.19, signaling moderate downside momentum, while Stoch RSI and CCI highlight briefly oversold conditions on short-term timeframes, and BBP indicates sellers currently dominate intraday activity. BIIB has risen $2.38 (1.31%) over the past week, with the price now in the lower part of its weekly range; weekly volatility stands at 6.63%. After an early-week rebound from near its low, the price has faded from weekly highs as sellers regain control. In today's session, BIIB is down 3.78%, accelerating the pullback from recent resistance.

Looking to next week, the projected range is $179.74 to $187.00, reflecting typical volatility for this stock and keeping the price between the 52-week low ($110.04) and high ($202.25). The probability of a further price increase is very high (more than 80%) given that RSI-W1, ADX-W1, MACD-W1, and MA-50-W1 all signal "Buy" or "Strong Buy". A price decline over the week is less likely. In the baseline scenario, BIIB consolidates between $180 and $187. A bullish scenario emerges if the price can reclaim and sustain above immediate resistance at $189, opening the way toward $192. Conversely, a bearish move would see BIIB break below the $178–$180 support cluster, putting further pressure on short-term sentiment despite the longer-term uptrend.

Previously it was reported that Biogen and Eisai presented new real-world data on long-term treatment persistence for early Alzheimer disease patients in the U.S. Any developments in Biogen’s pipeline or commercial strategy should be monitored closely, as they could influence sentiment and movement in the shares in the coming weeks.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.